Quralis Corporation

Cambridge, MA · Founded 2016 · Biotech · Private

Small molecule therapeutics targeting neurological diseases through novel approaches to neurobiology

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · quralis.com

Sector: Biotech
Headquarters: Cambridge, MA
Founded: 2016
Latest Form D: $20M, Sep 2025
Total capital: $119M

Federal grants: $1.1M; 3 awards · 2019–2020; Rank in peer group#280 of 326
Private capital raised: $118M; 4 Form D · last Sep 2025; 14 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 40 pending

Capital timeline

Latest events

Sep 2025Private capital raisedForm D · SEC · 4th filing$20M
Mar 2023Private capital raisedForm D · SEC · 3rd filing$60M
Sep 2022Private capital raisedForm D · SEC · 2nd filing$5M
Sep 2020Federal grantHealth and Human S · Phase II · Preclinical development of a Stathmin-2 splicing modulator for ALS$500K
Jul 2020Federal grantHealth and Human S · Phase I · Development of a therapeutic Kv7 opener to restore motor excitability in ALS$358K
May 2020Private capital raisedForm D · SEC · 1st filing$33.2M
Sep 2019Federal grantHealth and Human S · Phase I · Development of a human cellular TBK1 model for drug discovery in ALS$224K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

8months

from Quralis Corporation’s first federal award to its first private round.

First federal award · Sep 2019: Health and Human S · $224K
First Form D · May 2020: $33.2M · 1st Form D
Awards before first raise: 1 award

An association in public records, not a cause or a prediction.

Standing among 326 peers

Line = median

Biotech · Molecule

Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Amy C.D. SchulmanDirectorNamed in SEC Form D filings
Angela C.D. GengeExecutive OfficerNamed in SEC Form D filings
Anne C.D. WhitakerDirectorNamed in SEC Form D filings
Chris C.D. ThomajanExecutive OfficerNamed in SEC Form D filings
Cillian C.D. KingDirectorNamed in SEC Form D filings
Daniel C.D. ElbaumExecutive OfficerNamed in SEC Form D filings

Show all 19 people

Hagen C.D. CramerExecutive OfficerNamed in SEC Form D filings
Jason C.D. BrownExecutive OfficerNamed in SEC Form D filings
Johannes C.D. FruehaufDirectorNamed in SEC Form D filings
Jonathan C.D. BehrDirectorNamed in SEC Form D filings
Jonathan C.D. FlemingDirectorNamed in SEC Form D filings
Julio E. VegaExecutive OfficerNamed in SEC Form D filings
Kasper C.D. RoetDirector, Executive Officer, PromoterNamed in SEC Form D filings
Laia C.D. Crespo-MartinDirectorNamed in SEC Form D filings
Luc C.D. DochezDirectorNamed in SEC Form D filings
Michael C.D. HuttonDirectorNamed in SEC Form D filings
Roel C.D. BulthuisDirectorNamed in SEC Form D filings
Shafique C.D. ViraniExecutive OfficerNamed in SEC Form D filings
Vikas C.D. SharmaExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 40

Feb 13, 2025PendingTreatment Of Neurological Diseases Using Modulators Of UNC13A Gene TranscriptsUSPTOApplication 18715644
Jul 27, 2023PendingTreatment Of Neurological Diseases Using Modulators Of Gene TranscriptsUSPTOApplication 17928708
Nov 24, 2022PendingPPM1A Inhibitors And Methods Of Using SameUSPTOApplication 17621320

Show all 40 patent records

Treatment Of Neurological Diseases Using Modulators Of UNC13A Gene TranscriptsFeb 13, 2025 · Application 18715644Pending
Treatment Of Neurological Diseases Using Modulators Of Gene TranscriptsJul 27, 2023 · Application 17928708Pending
PPM1A Inhibitors And Methods Of Using SameNov 24, 2022 · Application 17621320Pending
Oligonucleotides And Methods Of Use For Treating Neurological DiseasesOct 20, 2022 · Application 17616350Pending
Gapmer Antisense Oligonucleotides With Modified Backbone ChemistriesApplication 18715682Pending
Splice Switcher Antisense Oligonucleotides With Modified Backbone ChemistriesApplication 18715684Pending
Modified UNC13A OligonucleotidesApplication PCTUS2024031911Pending
Functionalized Tetrahydrofuran Intermediate And Synthesis ThereofApplication PCTUS2024032038Pending
Modified UNC13A OligonucleotidesApplication 63470722Pending
Functionalized Tetrahydrofuran Intermediate And Synthesis ThereofApplication 63470639Pending
Gapmer Antisense Oligonucleotides With Modified Backbone ChemistriesApplication PCTUS2022051663Pending
Splice Switcher Antisense Oligonucleotides With Modified Backbone ChemistriesApplication PCTUS2022051740Pending
Treatment Of Neurological Diseases Using Modulators Of UNC13A Gene TranscriptsApplication PCTUS2022051713Pending
Treatment Of Neurological Diseases Using Modulators Of KCNQ2 Gene TranscriptsApplication PCTUS2022080853Pending
Treatment Of Neurological Diseases Using Modulators Of SMN2 Gene TranscriptsApplication PCTUS2022051716Pending
Treatment Of Neurological Diseases Using Modulators Of UNC13A Gene TranscriptsApplication 63398987Pending
Treatment Of Neurological Diseases Using Modulators Of SMN2 Gene TranscriptsApplication 63398992Pending
Treatment Of Neurological Diseases Using Modulators Of UNC13A Gene TranscriptsApplication 63350206Pending
PPM1A Gapmer Antisense Oligonucleotides For Treating Neurological DiseasesApplication 63285888Pending
ATXN2 Gapmer Antisense Oligonucleotides For Treating Neurological DiseasesApplication 63285696Pending
Treatment Of Neurological Diseases Using Modulators Of KCNQ2 Gene TranscriptsApplication 63285628Pending
Gapmer Antisense Oligonucleotides With Modified Backbone ChemistriesApplication 63285705Pending
Functionalized Tetrahydrofuran Intermediate And Synthesis ThereofApplication 19489178Pending
Modified UNC13A OligonucleotidesApplication 19484352Pending
Treatment Of Neurological Diseases Using Modulators Of SMN2 Gene TranscriptsApplication 63285631Pending
Mapt Gapmer Antisense Oligonucleotides For Treating Neurological DiseasesApplication 63285665Pending
Treatment Of Neurological Diseases Using Modulators Of UNC13A Gene TranscriptsApplication 63285786Pending
SOD1 Gapmer Antisense Oligonucleotides For Treating Neurological DiseasesApplication 63285692Pending
Splice Switcher Antisense Oligonucleotides With Modified Backbone ChemistriesApplication 63285933Pending
Treatment Of Neurological Diseases Using Modulators Of Gene TranscriptsApplication PCTUS2021035603Pending
Treatment Of Neurological Diseases Using Modulators Of Gene TranscriptsApplication 63119717Pending
PPM1A Inhibitors And Methods Of Using SameApplication PCTUS2020038703Pending
Oligonucleotides And Methods Of Use For Treating Neurological DiseasesApplication PCTUS2020035811Pending
Treatment Of Neurological Diseases Using Modulators Of Gene TranscriptsApplication 63033926Pending
Modulators Of STMN2 Expression And Activity, And Methods Of Using SameApplication 62949817Pending
Modulators Of STMN2 Expression And Activity, And Methods Of Using SameApplication 62914252Pending
PPM1A Inhibitors And Methods Of Using SameApplication 62871356Pending
PPM1A Inhibitors And Methods Of Using SameApplication 62864988Pending
Functionalized Tetrahydrofuran Intermediate And Synthesis ThereofApplication PCTUS2025050300Pending
Modulators Of STMN2 Expression And Activity, And Methods Of Using SameApplication 62856264Pending

BASEPAIR, INC.Similar federal contract value in Biotech · null in contracts
ADVANTAGE THERAPEUTICS, INCSimilar federal contract value in Biotech · null in contracts
ENVISAGENICS INCSimilar federal contract value in Biotech · null in contracts
Scribe Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
GENEVENTIV THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
BIOSYMETRICS, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.